Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/1999
12/21/1999US6004961 1,4-disubstituted piperazines
12/21/1999US6004958 Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
12/21/1999US6004938 Inositolglycans having insulin-like action
12/21/1999US6004931 Method for inhibiting growth hormone action
12/21/1999US6004925 Polypeptide anticholesterol agents; cardiovascular disorders, restenosis, atherosclerosis
12/21/1999CA2044280C Vitamin d analogues
12/21/1999CA2001171C Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
12/16/1999WO1999064598A2 Novel insulin analogs with enhanced zinc binding
12/16/1999WO1999064426A1 Heterobicyclic and tricyclic nitric oxide synthase inhibitors
12/16/1999WO1999064423A1 Furopyridine derivatives and their therapeutical use
12/16/1999WO1999064420A1 β-CARBOLINE COMPOUNDS
12/16/1999WO1999064410A1 BENZO(b)THIEPINE-1,1-DIOXIDE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE
12/16/1999WO1999064409A2 Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
12/16/1999WO1999064401A2 Imidazolyl derivatives and their use as somatostatin receptor ligands
12/16/1999WO1999064400A1 INHIBITORS OF p38
12/16/1999WO1999064394A1 Neuropeptide y5 receptor antagonists
12/16/1999WO1999064061A1 GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE
12/16/1999WO1999064029A1 Plant extract
12/16/1999WO1999064022A1 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system
12/16/1999WO1999064021A1 hCEPR RECEPTOR
12/16/1999WO1999064004A1 QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE
12/16/1999WO1999064002A1 Spiropiperidine derivatives as melanocortin receptor agonists
12/16/1999WO1999063998A1 Novel use of hiv protease inhibiting compounds
12/16/1999WO1999063976A2 Liver-selective glucocorticoid antagonist for treating diabetes
12/16/1999WO1999063974A2 Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
12/16/1999WO1999063973A2 PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
12/16/1999WO1999063841A1 Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability
12/16/1999WO1999050268A3 Substituted indolealkanoic acids
12/16/1999WO1999049877A3 Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions
12/16/1999DE19825804A1 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung 1,4-benzothiazepine 1,1-dioxide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use
12/16/1999CA2768882A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2768841A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2768828A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2768773A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2768682A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2335339A1 .beta.-carboline compounds
12/16/1999CA2334990A1 Novel use of hiv protease inhibiting compounds
12/16/1999CA2334970A1 Quinazolinone inhibitors of cgmp phosphodiesterase
12/16/1999CA2334945A1 Imidazolyl derivatives
12/16/1999CA2334872A1 Use of exendin-4 to treat impaired glucose tolerance
12/16/1999CA2334558A1 .alpha.-(1-piperazinyl)acetamido arenecarboxylic acid derivatives as antidiabetic agents
12/16/1999CA2334551A1 Spiropiperidine derivatives as melanocortin receptor agonists
12/16/1999CA2334449A1 Compositions comprising phytosterol, phytostanol or mixtures of both having enhanced solubility and dispersability and incorporation thereof into foods, beverages, pharmaceuticals, nutraceuticals and the like
12/16/1999CA2334116A1 Treatment of diabetes
12/16/1999CA2333691A1 Heterobicyclic and tricyclic nitric oxide synthase inhibitors
12/16/1999CA2333629A1 Furopyridine derivatives and their therapeutical use
12/15/1999EP0963987A2 Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole)
12/15/1999EP0963985A2 Di-or triaza-spiro(4,5)decane derivatives
12/15/1999EP0963983A1 Indol-2-ones as serotonin modulators
12/15/1999EP0963756A2 Inhibition of LDL oxidation and atherosclerosis
12/15/1999EP0963197A1 Guanylhydrazones useful for treating diseases associated with t cell activation
12/15/1999EP0725782B1 A 1 adenosine receptor agonists and antiagonists
12/15/1999EP0658110B1 Use of norastemizole for the treatment of allergic rhinitis
12/15/1999EP0631505B1 Use of a peptide
12/15/1999EP0610439B1 Pyrimidocycloalkanes as angiotensin ii antagonists
12/15/1999CN1238789A Water-soluble polymers for reduction of dietary phosphate or oxalate absorption
12/15/1999CN1238764A ApoB-secretion/MTP inhibitory amides
12/15/1999CN1238200A Medical capsule for regulating insulin and reducing blood and/or uric sugar
12/14/1999US6001972 Splicing variant of the epstein-barr virus-induced G-protein coupled receptor
12/14/1999US6001970 Modified human neuropeptide Y1 Receptors
12/14/1999US6001885 Retinoid inhibition of expression of VEGF
12/14/1999US6001882 Photoactivated hypericin and the use thereof
12/14/1999US6001881 Administering to treat arrhythmia, angina pectoris, ischemia, shock, cell proliferation, fibrotic diseases, prostate hyperplasia, fat metabolism disorders, and as a preservative for transplant organs, or to prepare a patient for surgery
12/14/1999US6001860 N-heteroaryl substituted thiourea or urea derivatives used to reduce cholesterol in blood stream, therefore useful to prevent cardiovascular disorders
12/14/1999US6001856 β-adrenergic agonists to reduce a wasting condition
12/14/1999US6001847 Chemical compounds
12/14/1999US6001358 Useful for treatment of autoimmune diseases
12/14/1999CA2181150C Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
12/14/1999CA2014971C Inhibitive agent against activity of alpha-amylase
12/12/1999CA2274202A1 Diaza-spiro[3,5]nonane derivatives
12/09/1999WO1999063102A1 ANTIDIABETIC ACTIVE COMPOUND(S) WF19353 AND PROCESS FOR THEIR FERMENTATIVE PREPARATION USING A FUNGUS OF THE GENUS $i(HELICOMYCES)
12/09/1999WO1999062939A2 Glycoproteins having lipid mobilising properties and therapeutic applications thereof
12/09/1999WO1999062902A1 N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors
12/09/1999WO1999062896A1 Novel polyoxypropylenepolyoxyethylene vitamin e and preparation thereof
12/09/1999WO1999062883A1 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
12/09/1999WO1999062872A1 New 3-aryl-2-hydroxypropionic acid derivative (i)
12/09/1999WO1999062871A1 New 3-aryl propionic acid derivatives and analogs
12/09/1999WO1999062870A1 New 3-aryl-2-hydroxypropionic acid derivative iii
12/09/1999WO1999062558A1 Insulin supplemented infant formula
12/09/1999WO1999062544A1 Activator protein of human acid maltase and uses thereof
12/09/1999WO1999062506A1 Use of compounds for the elevation of pyruvate dehydrogenase activity
12/09/1999WO1999062498A1 Spill resistant pharmaceutical compositions
12/09/1999WO1999062359A1 Matthiola seed oil, mixtures containing it and use thereof
12/09/1999WO1999062342A1 Acid and solvent modification of psyllium
12/09/1999WO1999046367A3 Methods of diagnosis and triage using cell activation measures
12/09/1999WO1999026583A3 Inhibtion of lipoprotein oxidation
12/09/1999DE19825447A1 Neue Insulinanaloga mit erhöhter Zinkbildung New insulin analogues with increased zinc Education
12/09/1999CA2334374A1 New 3-aryl propionic acid derivatives and analogs
12/09/1999CA2334107A1 New 3-aryl-2-hydroxypropionic acid derivative iii
12/09/1999CA2333988A1 Matthiola seed oil, mixtures containing it and use thereof
12/09/1999CA2333756A1 N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors
12/09/1999CA2317776A1 Acid and solvent modification of psyllium
12/08/1999EP0962150A2 Fat based food products
12/08/1999EP0961775A2 Purine l-nucleosides, analogs and uses thereof
12/08/1999EP0678086B1 Compounds having selectivity for retinoid x receptors
12/08/1999EP0664780B1 10-substituted 1,8-dihydroxy-9(10h) anthracenone pharmaceuticals
12/08/1999EP0643716B1 Quaternary nitrogen-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism
12/08/1999EP0634934B1 Use of dietary whey proteins for the treatment of hiv-seropositive individuals
12/08/1999CN1237955A Substituted phenols and thiophenols useful as antioxidant agents
12/08/1999CN1237905A Use of sibutramine analogues to prevent development of diabetes
1 ... 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 ... 1298